---
title: "Cumberland Pharma | 8-K: FY2025 Q1 Revenue: USD 11.71 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238987246.md"
datetime: "2025-05-06T21:03:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238987246.md)
  - [en](https://longbridge.com/en/news/238987246.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238987246.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/238987246.md) | [繁體中文](https://longbridge.com/zh-HK/news/238987246.md)


# Cumberland Pharma | 8-K: FY2025 Q1 Revenue: USD 11.71 M

Revenue: As of FY2025 Q1, the actual value is USD 11.71 M.

EPS: As of FY2025 Q1, the actual value is USD 0.08.

EBIT: As of FY2025 Q1, the actual value is USD 1.254 M.

### Segment Revenue

-   Cumberland Pharmaceuticals Inc. reported net revenues of $11.7 million for the first quarter of 2025, marking a 38% increase compared to the prior year period.
-   Revenue breakdown includes $3.5 million from Kristalose®, $2.3 million from Sancuso®, $1.4 million from Vibativ®, and $1.3 million from Caldolor®.

### Operational Metrics

-   Net income for the first quarter of 2025 was approximately $1.3 million, compared to a net loss of $1.9 million in the same period of 2024.
-   Operating income was $1.3 million, a significant improvement from an operating loss of $1.9 million in the first quarter of 2024.
-   Total operating expenses for the quarter were $10.4 million.

### Cash Flow

-   Cash flow from operations was $3.9 million for the first quarter of 2025, compared to - $2.1 million in the same period of 2024.

### Unique Metrics

-   Cumberland ended the quarter with approximately $70 million in total assets, $41.6 million in liabilities, and $28.7 million of shareholders’ equity.

### Outlook / Guidance

-   Cumberland Pharmaceuticals is optimistic about future growth driven by strong performance from approved brands, expansion of international partnerships, progress in clinical development programs, and potential strategic acquisitions.

### Related Stocks

- [Cumberland Pharmaceuticals Inc. (CPIX.US)](https://longbridge.com/en/quote/CPIX.US.md)

## Related News & Research

- [CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT | CPIX Stock News](https://longbridge.com/en/news/268960394.md)
- [Cipla's US unit recalls 400+ cartons of generic anti-cancer drug: USFDA](https://longbridge.com/en/news/278249419.md)
- [CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH | CPIX Stock News](https://longbridge.com/en/news/264293730.md)
- [BUZZ-Cumberland jumps as heart drug for muscle‑wasting disease gets FDA's fast-track tag](https://longbridge.com/en/news/274829315.md)